HLB Pharmaceutical Co. Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

HLB Pharmaceutical Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.86 Billion ≈ $1.26 Million USD) by net assets (₩120.95 Billion ≈ $81.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 047920 market cap for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of HLB Pharmaceutical Co. Ltd (2014–2024)

Cash flow conversion efficiency of HLB Pharmaceutical Co. Ltd from 2014 to 2024. This chart illustrates how HLB Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 047920 live share price for real-time trading data and today's change.

HLB Pharmaceutical Co. Ltd Cash Flow Conversion Ratio Explained

HLB Pharmaceutical Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

HLB Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Review 047920 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Peña Verde S.A.B MX:PV	0.005x
Hawthorn Bancshares Inc NASDAQ:HWBK	0.087x
ACELYRIN, INC. Common Stock NASDAQ:SLRN	-0.096x
Turtle Beach Corporation NASDAQ:TBCH	0.080x
China General Plastics Corp TW:1305	0.025x
Amazing Microelectronic TWO:6411	0.027x
DFI Inc TW:2397	0.038x
Kardan Israel Ltd TA:KRDI	-0.092x

Annual Cash Flow Conversion Efficiency for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of HLB Pharmaceutical Co. Ltd from 2014 to 2024. Also see HLB Pharmaceutical Co. Ltd asset portfolio for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩116.40 Billion ≈ $78.88 Million	₩6.84 Billion ≈ $4.64 Million	0.059x	+128.28%
2023-12-31	₩88.15 Billion ≈ $59.74 Million	₩-18.32 Billion ≈ $-12.41 Million	-0.208x	-546.24%
2022-12-31	₩85.93 Billion ≈ $58.23 Million	₩-2.76 Billion ≈ $-1.87 Million	-0.032x	-90.74%
2021-12-31	₩78.38 Billion ≈ $53.12 Million	₩-1.32 Billion ≈ $-895.45K	-0.017x	-86.48%
2020-12-31	₩44.62 Billion ≈ $30.24 Million	₩-403.36 Million ≈ $-273.35K	-0.009x	-111.60%
2019-12-31	₩17.36 Billion ≈ $11.76 Million	₩1.35 Billion ≈ $917.12K	0.078x	+174.56%
2018-12-31	₩17.00 Billion ≈ $11.52 Million	₩-1.78 Billion ≈ $-1.20 Million	-0.105x	-124.00%
2017-12-31	₩16.80 Billion ≈ $11.39 Million	₩-784.30 Million ≈ $-531.51K	-0.047x	-313.95%
2016-12-31	₩18.90 Billion ≈ $12.81 Million	₩-213.11 Million ≈ $-144.42K	-0.011x	+82.16%
2015-12-31	₩12.18 Billion ≈ $8.25 Million	₩-769.59 Million ≈ $-521.54K	-0.063x	-119.72%
2014-12-31	₩4.81 Billion ≈ $3.26 Million	₩1.54 Billion ≈ $1.05 Million	0.320x	--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$228.94 Million

₩337.83 Billion KRW

Market Cap Rank

#15919 Global

#556 in Korea

Share Price

₩10300.00

Change (1 day)

+1.48%

52-Week Range

₩6170.00 - ₩20900.00

All Time High

₩41100.00